DERM
NASDAQ · Pharmaceuticals
Journey Medical Corp
$6.63
-0.32 (-4.60%)
Financial Highlights (FY 2026)
Revenue
91.37M
Net Income
-23,881,556
Gross Margin
56.7%
Profit Margin
-26.1%
Rev Growth
-3.8%
D/E Ratio
1.30
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 56.7% | 56.7% | 62.4% | 62.4% |
| Operating Margin | -22.4% | -20.1% | 16.9% | 16.2% |
| Profit Margin | -26.1% | -24.8% | 17.9% | 16.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 91.37M | 95.02M | 106.46M | 91.38M |
| Gross Profit | 51.82M | 53.88M | 66.48M | 57.06M |
| Operating Income | -20,430,142 | -19,121,389 | 17.94M | 14.85M |
| Net Income | -23,881,556 | -22,351,705 | 19.04M | 15.46M |
| Gross Margin | 56.7% | 56.7% | 62.4% | 62.4% |
| Operating Margin | -22.4% | -20.1% | 16.9% | 16.2% |
| Profit Margin | -26.1% | -24.8% | 17.9% | 16.9% |
| Rev Growth | -3.8% | -3.8% | +23.5% | +18.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 65.32M | 65.32M | 81.05M | 98.09M |
| Total Equity | 50.25M | 50.25M | 109.66M | 130.87M |
| D/E Ratio | 1.30 | 1.30 | 0.74 | 0.75 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -20,429,522 | -20,183,076 | 19.03M | 16.26M |
| Free Cash Flow | — | — | 11.82M | 11.85M |